Shanghai, China, 28 December 2021 — MicroPort^® CardioFlow Medtech Corporation (MicroPort^® CardioFlow) recently announced that its latest transcatheter aortic valve implantation (TAVI) solution, the new-generation VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™) has completed the submission of applications materials for the EU CE certification.

VitaFlow Liberty™  is the world's only electric retrievable transcatheter aortic valve system, offering outstanding stability during  procedure and hemodynamics post procedure, that will improve the quality of life for patients with aortic valve disease. It inherits the advantages of the VitaFlow™ in terms of valve design，featuring a hybrid density self-expanding stent, bovine pericardial leaflets, and a high double-layer PET skirt design. This design offers robust radial force, improved coaxiality during deployment, and effectively reduces the incidence of perivalvular leakage post procedure. Moreover, its breakthrough upgraded delivery system incorporates a unique and innovative double-reinforced spiral structure that ensures rapid, stable, and precise release and retrieval. This system also provides flexibility, allowing for 360-degree bending of the valve segment.

Since the launch of VitaFlow™ series of TAVI product, MicroPort^® CardioFlow has successfully entered into over 500 heart centers across China, becoming a major player in the Chinese heart valve market. The launch of Vitaflow Liberty™ is not just an upgrade of the delivery system with added recapturing functionality, it is a comprehensive optimization for the whole system that places the solution at the leading edge internationally. Since its launch, VitaFlow Liberty™ has received positive reviews by clinicians in China and across the globe for its unparalleled control experience and clinical results. The submission of applications materials for the EU CE certification of Vitaflow Liberty™ marks another solid step in the international expansion of CardioFlow Medtech.

With years of R&D experience and technological foundation, MicroPort^® CardioFlow has built an integrated platform focusing on the R&D, clinical, manufacturing and commercialization of medical devices for structural heart disease. In the future, MicroPort^® CardioFlow will continue to adhere to the mission of“provide trustworthy and universal access to state-of-the-art total solutions to treat structural heart diseases ", further leverage the advantages of the platform, to continuously accelerate the introduction of internationally leading products and progressively expand internationally.